AI-powered small-molecule drug discovery platforms
Strategic Profile
ChemPass AI™'s competitive advantage lies in its ability to generate novel molecules while optimizing multiple critical parameters from the earliest stages of design. This powerful platform significantly improves success rates while reducing development time and costs. The company is expanding its pharma pipeline while maintaining agricultural applications as a secondary focus area.
Cyborg Score Rationale
Evogene possesses strong AI-driven technology with demonstrated pharma partnerships and clinical-stage assets, but faces significant financial headwinds. Net loss for Q1 2026 was approximately $5.9 million, and 2025 revenue was approximately $3.9 million with operating expenses at ~$13.8 million. The company's ongoing strategic restructuring and low market capitalization create execution risk despite strong technology.
Top Insights
In February 2026, Biomica (Evogene subsidiary) granted Shanghai Lishan Biopharmaceuticals an exclusive worldwide license for BMC128, a microbiome-based therapeutic showing promise in renal and lung cancer, bringing China's clinical capabilities with Israel's microbiome science innovation
Dr. Olga Nissan was appointed Vice President of Business Development effective January 2026, a seasoned biotech executive with experience in R&D, clinical development, and AI-enabled drug discovery
Evogene presented at BIO-Europe Spring 2026 (March 23-25) with focus on pharma division achievements and AI-driven small-molecule discovery breakthroughs
Post-2025 strategic refocus narrows company scope to ChemPass AI platform for pharma and agriculture, divesting non-core assets like Lavie Bio to improve capital efficiency
Named Competitors
DeepMind for drug discovery — AI-powered protein structure prediction and molecular design
Atomwise — AI platform for small-molecule drug discovery
Exscientia — AI-powered drug discovery and optimization platform
Insilico Medicine — Generative AI for drug discovery and biomarker development
Recent Developments
(May 2026) Q1 2026 financial results reported with $5.9 million net loss; CEO emphasized execution on ChemPass AI advancement and pipeline expansion
(March 2026) Presented pharma discovery achievements at BIO-Europe Spring 2026 conference highlighting AI-driven small-molecule discovery capabilities
(February 2026) Biomica (subsidiary) granted Shanghai Lishan Biopharmaceuticals exclusive worldwide license for BMC128, a microbiome-based therapeutic in early clinical development
(January 2026) Appointed Dr. Olga Nissan as Vice President of Business Development to scale small-molecule discovery and expand collaborations
Open the full interactive Evogene Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.